The Cancer Institute Hospital of JFCR ( Site 2000)(6.7 mi away)Contact
+92 other location
This study will investigate the utility of biomarker-based triage for study participants with
advanced non-small cell lung cancer (NSCLC) without prior systemic therapy. Study
participants within groups defined by a biomarker-based classifier (gene expression profile
[GEP] and tumor mutational burden [TMB]) will be randomized to receive pembrolizumab in
combination with quavonlimab (MK-1308), favezelimab (MK-4280), or lenvatinib. The primary
hypotheses are as follows: In participants receiving pembrolizumab in combination with either
quavonlimab, favezelimab, or lenvatinib, the Objective Response Rate (ORR) will be 1) greater
than 5% among participants with low GEP and low TMB, 2) greater than 20% among participants
with low GEP and high TMB, 3) greater than 20% among participants with high GEP and low TMB,
and 4) greater than 45% among participants with high GEP and high TMB.
After Amendment 5, participants can receive 800 mg of favezelimab every 3 weeks (Q3W)
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.